Multiple Myeloma Clinical Trial
Official title:
Reduced-Intensity Preparative Regiment With Fludarabine, Busulfan, And Alemtuzumab (Campath 1H) Followed By Allogeneic Hematopoietic Stem Cell Transplant For Malignant And Non-Malignant Hematological Diseases
Blood disorders such as leukemia or lymphoma or hemoglobinopathies can benefit from
receiving an allogeneic (meaning that the cells are from a donor) stem cell transplant. Stem
cells are created in the bone marrow. They grow into different types of blood cells that the
body needs, including red blood cells, white blood cells, and platelets. In a transplant,
the body's stem cells would be killed and then replaced by stem cells from the donor.
Usually, patients are given very high doses of chemotherapy (drugs which kill cancer cells)
prior to receiving a stem cell transplant. However, patients that are older, have received
several prior treatments, or have other organ diseases are at a high risk of getting
life-threatening treatment-related side effects from high doses of chemotherapy. Over the
past several years, some doctors have begun to use lower doses of chemotherapy for preparing
patients for a stem cell transplant.
A condition that can occur after a stem cell transplant from a donor is Graft Versus Host
Disease (GVHD). It is a rare but serious disorder that can strike persons whose immune
system is suppressed and have received either a blood transfusion or a bone marrow
transplant. Symptoms may include skin rash, intestinal problems similar to inflammation of
the bowel and liver dysfunction.
This research study uses a combination of lower-dose chemotherapy agents that is slightly
different from those that have been used before.
The medicines that will be used in this study are Fludarabine, Busulfan, both chemotherapy
medicines, and Campath. Campath is a monoclonal antibody (a type of substance produced in
the laboratory that binds to cancer cells). It helps the immune system see the cancer cell
as something that needs to be destroyed.
This research study will help us learn if using Fludarabine, Busulfan and Campath prior to
an allogeneic stem cell transplant can provide treatment for blood disorders while
decreasing the incidence of side effects.
Status | Terminated |
Enrollment | 4 |
Est. completion date | October 2010 |
Est. primary completion date | February 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A to 70 Years |
Eligibility |
Inclusion Criteria: 1. Diagnosis of myelodysplastic and myeloproliferative disorders, acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, multiple myeloma, plasma cell dyscrasia, lymphoproliferative disorders (non-Hodgkin lymphoma, hairy cell leukemia, chronic lymphocytic leukemia, and Hodgkin's disease) and non malignant hematologic diseases considered treatable with an allogeneic transplant including but not limited to bone marrow failure syndrome, hemoglobinopathy and severe immunodeficiency states. 2. Performance status 0-2 on Zubrod scale 3. Ejection fraction > 30% 4. AST/ALT and bilirubin not > 4 times normal 5. FEV1 greater than 1.0 and diffusion capacity > 40% 6. Age birth to 70 years of age 7. Conditions that increase treatment related mortality (need more than one to be eligible): - Age > 35 years - EF of less than 45% - DLCO less than 50% or FEV1 50-75% of predicted value - Diabetes mellitus - Renal insufficiency, defined by increase in serum creatinine level of 1.5 times ULN or decrease in GFR by 25% - Prior recent history of systemic fungal infection - 3rd or greater remission of AML or ALL - More than 1 year of diagnosis (CML or myeloma patients only) - Multiple types of treatment regimens (equal to or more than 3) - Prior autologous or allogeneic stem cell transplantation - Significant Grade III or IV neurologic or hepatic toxicity as defined by NCI CTC toxicity from previous treatment - No matched sibling donor 8. Available healthy donor without any contraindications for donation - 5/6 or 6/6 related - 5/6 or 6/6 unrelated (molecular typing for DRB1) 9. Patient and/or responsible person able to understand and sign consent 10. For women of childbearing potential, negative pregnancy test Exclusion Criteria: 1. Pregnant and lactating women or women unwilling to use contraception. 2. HIV positive patient. 3. Uncontrolled intercurrent infection. 4. Refractory AML or ALL. 5. Untreated blast crisis for CML. 6. Uncontrolled high-grade lymphoproliferative disease/lymphoma. 7. Unstable angina and uncompensated congestive heart failure (Zubrod of 3 or greater). 8. Severe chronic pulmonary disease requiring oxygen (Zubrod of 3 or greater). 9. Hemodialysis dependent. 10. Active Hepatitis or cirrhosis with total bilirubin, SGOT, and SGPT greater than 3 x normal. 11. Serum creatinine >2x ULN. 12. Unstable cerebral vascular disease and recent hemorrhagic stroke (less than 6 months). 13. Active CNS disease from hematological disorder. |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Texas Children's Hospital | Houston | Texas |
United States | The Methodist Hospital | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
Baylor College of Medicine | Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital System |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Patients With Successful Donor Engraftment | Each patient will be classified as a success or failure. A success will be defined as engraftment of at least 35% of cells 100 days after transplant. | 100 days | No |
Secondary | Number of Treatment Related Grade III or IV Non-hematological Toxicity | 100 days | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |